Viridian Therapeutics, Inc.\DE
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(333,229) | $(222,246) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 47,606 | 32,314 |
| Non-cash interest expense | 13,486 | 308 |
| Depreciation and amortization | 581 | 340 |
| Accretion and amortization of available-for-sale securities | (4,864) | (5,005) |
| Non-cash lease expense | (46) | (30) |
| Change in fair value of derivative liability | (8,410) | — |
| Loss on extinguishment of debt | 4,113 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (29,782) | — |
| Inventory | (85) | — |
| Prepaid expenses and other assets | (5,771) | 8,849 |
| Accounts payable | 614 | 7,942 |
| Accrued liabilities | (1,449) | (5,109) |
| Other liabilities | (236) | — |
| Unbilled revenue | (279) | (70,000) |
| Net cash used in operating activities | (317,751) | (252,637) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (645,594) | (141,084) |
| Maturities of marketable securities | 527,734 | 443,196 |
| Milestone payment related to licensed intellectual property | (10,000) | — |
| Purchases of property and equipment | (1,699) | (255) |
| Net cash provided by (used in) investing activities | (129,559) | 301,857 |
| Cash flows from financing activities: | ||
| Proceeds from the sale of convertible notes | 250,000 | — |
| Proceeds from the issuance of common stock in offerings | 143,750 | — |
| Proceeds from sale of common stock in at-the-market offerings | — | 14,904 |
| Payments of issuance costs associated with the sale of common stock | (8,778) | (416) |
| Payments of issuance costs associated with the sale of convertible notes | (8,014) | — |
| Proceeds from sale of future revenue | 75,000 | — |
| Prepayment of long-term debt | (54,700) | — |
| Proceeds from the exercise of warrants | — | 1,618 |
| Proceeds from issuance of common stock upon exercises of stock options | 10,560 | 3,607 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,270 | 1,120 |
| Net cash provided by financing activities | 409,088 | 20,833 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (38,222) | 70,053 |
| Cash, cash equivalents, and restricted cash at beginning of period | 212,382 | 99,594 |
| Cash, cash equivalents, and restricted cash at end of period | $174,160 | $169,647 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $2,227 | $1,362 |
| Issuance of common stock upon the conversion of convertible preferred stock | $34,032 | $— |
| Purchase of property and equipment included in accounts payable and accrued liabilities | $418 | $17 |
| Deferred issuance costs included in accounts payable and accrued liabilities | $— | $528 |
| Right-of-use asset obtained in exchange for new lease liability | $783 | $729 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.